Article information
El amplio desarrollo de la investigación en el campo de la consolidación ósea ha propiciado la existencia de nuevas líneas de investigación que, aunque actualmente no están disponibles para su uso clínico, sí tienen grandes perspectives de éxito a medio y largo plazo. Entre estas nuevas técnicas destacan los estimuladores locales y matrices inteligentes, las células mesenquimales o la terapia génica. En este artículo se presenta el estado actual de desarrollo de esta tecnología emergente.
Palabras clave:
PTH
estimuladores locales
células madre
terapia génica
consolidación ósea
The outstanding development of research in the field of bone healing has brought about new lines of research into procedures that, althoug not currently available for clinical use, offer great possibilities of being successful in the medium and long term. Amongst these new techniques, it is worthwhile highlighting local stimulators and smart matrices, messenchymal cells and gene therapy. In this article we present an update on the development of these emerging technologies.
Keywords:
PTH
local stimulators
stem cells
gene therapy
bone healing
Full text is only aviable in PDF
Bibliografía
[1]
Cosman F..
Anabolic therapy for osteoporosis: parathyroid hormone..
Curr Osteoporos Rep. , 3 (2005), pp. 143-149
[2]
Alkhiary Y.M., Gerstenfeld L.C., Krall E., Westmore M., Sato M., Mitlak B.H., et-al..
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)..
J Bone Joint Surg Am. , 87A (2005), pp. 731-741
[3]
Nakajima A., Shimoji N., Shiomi K., Shimizu S., Moriya H., Einhorn T.A., et-al..
Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34)..
J Bone Miner Res. , 17 (2002), pp. 2038-2047
[4]
Murota S.I., Onodera M., Morita I..
Regulation of angiogenesis by controlling VEGF receptor..
Ann N Y Acad Sci. , 902 (2000), pp. 208-212
[5]
Alagiakrishnan K., Juby A., Hanley D., Tymchak W., Sclater A..
Role of vascular factors in osteoporosis..
J Gerontol A Biol Sci Med Sci. , 58 (2003), pp. 362-366
[6]
Murphy W.L., Peters M.C., Kohn D.H., Money D.J..
Sustained release of vascular endothelial growth factor from mineralized poly (lactide-co-glycolide) scaffolds for tissue engineering..
Biomaterials. , 21 (2000), pp. 2521-2527
[7]
Eckardt H., Ding M., Lind M., Hansen E.S., Christensen K.S., Hvid I..
Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model..
J Bone Joint Surg Br. , 87(B) (2005), pp. 1434-1438
[8]
Philbrick W.M., Wysolmerski J.J., Galbraith S., Holt E., Orloff J.J., Yang K.H., et-al..
Defining the roles of parathyroid hormone-related protein in normal physiology..
Physiol Rev. , 76 (1996), pp. 127-173
[9]
Strewler G.J..
The physiology of parathyroid hormone-related protein..
N Engl J Med. , 342 (2000), pp. 177-185
[10]
Martínez P., Esbrit P., Rodrigo A., Álvarez-Arroyo M.V., Martínez M.E..
Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells..
Osteoporos Int. , 13 (2002), pp. 874-881
[11]
Bruder S., Fink D.J., Caplan A.I..
Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy..
J Cell Biochem. , 56 (1994), pp. 283-294
[12]
Körbling M., Estrov Z..
Adult Stem Cells for Tissue Repair. A New Therapeutic Concept?..
N Engl J Med. , 349 (2003), pp. 570-582
[13]
Salgado A.J., Coutinho O.P., Reis R.L..
None Tissue Engineering: State of the Art and Future Trends..
Macromol Biosc. , 4 (2004), pp. 743-765
[14]
Banwart J.C., Asher M.A., Hassanein R.S..
Iliac crest bone graft harvest donor site morbidity. A statistical evaluation..
Spine. , 20 (1995), pp. 1055-1060
[15]
Koller M.R., Palsson M.A., Manchel I., Maher R.J., Palsson B.O..
Tissue culture surface characteristics influence the expansion of human bone marrow cells..
Biomaterials. , 19 (1998), pp. 1963-1972
[16]
Lundell B.I., Mandalam R.K., Smith A.K..
Clinical scale expansion of cryopreserved small volume whole bone marrow aspirates produces sufficient cells for clinical use..
J Hematother. , 8 (1999), pp. 115-127
[17]
Bruder S.P., Kurth A.A., Shea M., Hayes W.C., Jaiswal N., Kadiyala S..
Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells..
J Orthop Res. , 16 (1998), pp. 155-162
[18]
Endres M., Hutmacher D.W., Salgado A.J., Kaps C., Ringe J., Reis R.L..
Osteogenic Induction of Human Bone Marrow-Derived Mesenchymal Progenitor Cells in Novel Synthetic Polymer–Hydrogel Matrices..
Tissue Eng. , 9 (2003), pp. 689-702
[19]
Cato T., Frank K.K.O., et-al..
Studies on the development of a tissue engineered matrix for bone regeneration..
Cells and Materials. , 8 (1998), pp. 175-181
[20]
Bachier C.R., Gokmen E., Teale J., Lanzkron S., Childs C., Franklin W..
Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer..
Exp Hematol. , 27 (1999), pp. 615-623
[21]
Jaffurs D., Evans C.H..
The human genome project: implications for the treatment musculoskeletal disease..
J Am Acad Orthop Surg. , 6 (1998), pp. 1-14
[22]
Niyibizi C, Mi Z, Robbins PD. Potential gene therapy for diseases of bone. En: Rosier RN, Evans CH, directores. Molecular Biology in Orthopedics. Rosemont Illinois: AAOS; 2001. p. 67-374..
[23]
Kaplan FS, Ahn J, Serrano de la Peña L. Fibrodysplasia ossificans progressive: deciphering the molecular pathways of ectopic skeletogenesis. En: Rosier RN, Evans CH, directores. Molecular Biology in Orthopedics. Rosemont Illinois: AAOS; 2001. p. 5-105..
[24]
Evans C.H., Robbins P.D., Ghivizzani S.C..
Possible orthopedic applications of gene therapy..
J Bone Joint Surg Am. , 77(A) (1995), pp. 1103-1114
[25]
Evans C.H., Ghivizzani S.C., Herndon J.H..
Clinical trials in the gene therapy of arthritis..
Clin Orthop. , 379 (2000), pp. S300-S307
[26]
Evans C.H., Ghivizzani S.C., Herndon J., Robbins P.D..
Terapia génica para el tratamiento de las enfermedades musculoesqueléticas..
J Am Acad Orthop Surg (ed Esp). , 4 (2005), pp. 302-304
[27]
Kostenuik P.J., Bolton B., Morony S., Daris M., Genz Z., Carter C., et-al..
Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice..
Bone. , 34 (2004), pp. 656-664
[28]
Mc Ilwraith C.W., Frisbie D.D..
Breack out session: Osteoarthritis..
Clin Orthop. , 379 (2000), pp. S311
[29]
Bandara G., Robbins P.D., Georescu H.O., Mueller G.M., Glorioso J.C., Evans C.H..
Gene transfer to synoviocytes. Prospects for gene treatment of artritis..
DNA Cell Biol. , 11 (1992), pp. 227-331
[30]
Franceschi R.T..
Biological approaches to bone regeneration by gene therapy..
J Dent Res. , 84 (2005), pp. 1093-1103
[31]
Buckwalter J.A..
Can tissue engineerig help orthopedic patients? Clinical needs and criteria for success..
Can tissue engineerig help orthopedic patients? Clinical needs and criteria for success., pp. 16
[32]
Einhorn T.A..
The cell and molecular biology of fracture healing..
Clin Orthop. , S355 (1998), pp. 7-21
[33]
Einhorn T.A..
Clinical applications of human recombinant BMPs: early experiences and future developments..
J Bone Joint Surg Am. , 85(A) (2003), pp. 82-88
[34]
Caplan A.I., Goldberg V.M..
Principles of tissue engineered regeneration of skeletal tissues..
Clin Orthop. , 367S (1999), pp. S12-S16
[35]
Cho T.J., Gerstenfeld L.C., Einhorn T.A..
Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing..
J Bone Miner Res. , 17 (2002), pp. 513-520
[36]
Lieberman J.R..
Breakout Session 3: Fracture healing and other non genetic diseases of bone..
Cin Orthop. , 379S (2000), pp. S156-S158
